Chemistry:Tregalizumab
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD4 |
| Clinical data | |
| Other names | BT-061 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Tregalizumab is an immunomodulator.[1] It is also known as BT-061. Tregalizumab binds to domain 2 of CD4,[2] and activates Regulatory T cells (Tregs).[3]
References
- ↑ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104". WHO Drug Information 24 (4). https://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf.
- ↑ "A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway". Immunology and Cell Biology 93 (4): 396–405. April 2015. doi:10.1038/icb.2014.102. PMID 25512343.
- ↑ "Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells". Frontiers in Immunology 7: 11. Jan 2016. doi:10.3389/fimmu.2016.00011. PMID 26834751.
 |  |
